Potential directions for drug development for osteoarthritis

Bibliography

• Aigner T, Sachse A, Gebhard PM, Roach HI. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev 2006;58:128-49
   PubMed Web of Science ®Google Scholar
• Goldring MB. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 2006;20:1003-25
   PubMed Web of Science ®Google Scholar
• Roach HI, Tilley S. The pathogenesis of osteoarthritis. In: Bronner F, Farach-Carson MC, editors, Bone and osteoarthritis, volume 4, topics in bone biology; 2007. p. 1-18
   Google Scholar
• Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 2005;35:1-10
   PubMed Web of Science ®Google Scholar
• Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 2007;24:629-42
   PubMed Web of Science ®Google Scholar
• Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007;57:1410-8
   PubMed Web of Science ®Google Scholar
• Fajardo M, Di Cesare PE. Disease-modifying therapies for osteoarthritis: current status. Drugs Aging 2005;22:141-61
   PubMed Web of Science ®Google Scholar
• Berenbaum F. The quest for the Holy Grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther 2007;9:111
   PubMedGoogle Scholar
• Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007;33:197-217
   PubMed Web of Science ®Google Scholar
• Suematsu A, Tajiri Y, Nakashima T, et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol 2007;17:17-23
   PubMedGoogle Scholar
• Aigner T, Stove J. Collagens – major component of the physiological cartilage matrix, major target of cartilage degeneration, major tool in cartilage repair. Adv Drug Deliv Rev 2003;55:1569-93
   PubMed Web of Science ®Google Scholar
• Reginato AM, Olsen BR. The role of structural genes in the pathogenesis of osteoarthritic disorders. Arthritis Res 2002;4:337-45
   PubMedGoogle Scholar
• Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res 2003;15:426-39
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53:523-37
   PubMed Web of Science ®Google Scholar
• Pritzker KP, Gay S, Jimenez SA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006;14:13-29
   PubMed Web of Science ®Google Scholar
• Lajeunesse D, Reboul P. Subchondral bone in osteoarthritis: a biologic link with articular cartilage leading to abnormal remodeling. Curr Opin Rheumatol 2003;15:628-33
   PubMed Web of Science ®Google Scholar
• Verzijl N, DeGroot J, Thorpe SR, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000;275:39027-31
   PubMed Web of Science ®Google Scholar
• Maroudas A, Bayliss MT, Uchitel-Kaushansky N, et al. Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. Arch Biochem Biophys 1998;350:61-71
   PubMed Web of Science ®Google Scholar
• Roach HI, Yamada N, Cheung KS, et al. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum 2005;52:3110-24
   PubMed Web of Science ®Google Scholar
• Clark IM, Parker AE. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 2003;7:19-34
   PubMed Web of Science ®Google Scholar
• Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006;20:983-1002
   PubMed Web of Science ®Google Scholar
• Burrage PS, Brinckerhoff CE. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 2007;8:293-303
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Bishop J, Bottomley KM, et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997;121:540-6
   PubMed Web of Science ®Google Scholar
• Sabatini M, Lesur C, Thomas M, et al. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis Rheum 2005;52:171-80
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Protein kinases in chondrocyte signaling and osteoarthritis. Clin Orthop Relat Res 2004;S145-51
   Google Scholar
• Malemud CJ. Small molecular weight inhibitors of stress-activated and mitogen-activated protein kinases. Mini Rev Med Chem 2006;6:689-98
   PubMed Web of Science ®Google Scholar
• Pratta MA, Yao W, Decicco C, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem 2003;278:45539-45
   PubMed Web of Science ®Google Scholar
• Arner EC. Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol 2002;2:322-9
   PubMed Web of Science ®Google Scholar
• Glasson SS, Askew R, Sheppard B, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004;50:2547-58
   PubMed Web of Science ®Google Scholar
• Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005;434:644-8
   PubMed Web of Science ®Google Scholar
• Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;434:648-52
   PubMed Web of Science ®Google Scholar
• Song RH, Tortorella MD, Malfait AM, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007;56:575-85
   PubMed Web of Science ®Google Scholar
• Goldring MB. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001;1:817-29
   PubMed Web of Science ®Google Scholar
• Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004;S27-36
   Google Scholar
• Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001;9:539-52
   PubMed Web of Science ®Google Scholar
• Koshy PJ, Lundy CJ, Rowan AD, et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002;46:961-7
   PubMed Web of Science ®Google Scholar
• Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237-46
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005;52:128-35
   PubMed Web of Science ®Google Scholar
• Barksby HE, Hui W, Wappler I, et al. Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair. Arthritis Rheum 2006;54:540-50
   PubMed Web of Science ®Google Scholar
• Abramson SB, Attur M, Amin AR, Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 2001;3:535-41
   PubMedGoogle Scholar
• Scher JU, Pillinger MH, Abramson SB. Nitric oxide synthases and osteoarthritis. Curr Rheumatol Rep 2007;9:9-15
   PubMedGoogle Scholar
• Vuolteenaho K, Moilanen T, Knowles RG, Moilanen E. The role of nitric oxide in osteoarthritis. Scand J Rheumatol 2007;36:247-58
   PubMed Web of Science ®Google Scholar
• Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003;11:747-55
   PubMed Web of Science ®Google Scholar
• Regan E, Flannelly J, Bowler R, et al. Extracellular superoxide dismutase and oxidant damage in osteoarthritis. Arthritis Rheum 2005;52:3479-91
   PubMed Web of Science ®Google Scholar
• Davies CM, Guilak F, Weinberg JB, Fermor B. Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis. Osteoarthritis Cartilage 2007
   Google Scholar
• Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 2004;S37-46
   Google Scholar
• Alvarez-Soria MA, Largo R, Sanchez-Pernaute O, et al. Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. Rheumatol Int 2007;27:911-7
   PubMed Web of Science ®Google Scholar
• Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003;42(Suppl 2):ii3-10
   PubMedGoogle Scholar
• Fan Z, Soder S, Oehler S, et al. Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am J Pathol 2007;171:938-46
   PubMed Web of Science ®Google Scholar
• Benito MJ, Veale DJ, FitzGerald O, et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005;64:1263-7
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Cytokines as therapeutic targets for osteoarthritis. BioDrugs 2004;18:23-35
   PubMed Web of Science ®Google Scholar
• Moos V, Fickert S, Muller B, et al. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 1999;26:870-9
   PubMed Web of Science ®Google Scholar
• Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001;44:585-94
   PubMed Web of Science ®Google Scholar
• Wu W, Billinghurst RC, Pidoux I, et al. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum 2002;46:2087-94
   PubMed Web of Science ®Google Scholar
• Rowan AD, Hui W, Cawston TE, Richards CD. Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. Am J Pathol 2003;162:1975-84
   PubMed Web of Science ®Google Scholar
• Fan Z, Bau B, Yang H, Aigner T. IL-1beta induction of IL-6 and LIF in normal articular human chondrocytes involves the ERK, p38 and NFkappaB signaling pathways. Cytokine 2004;28:17-24
   PubMed Web of Science ®Google Scholar
• Amos N, Lauder S, Evans A, et al. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology (Oxford) 2006;45:1201-9
   PubMed Web of Science ®Google Scholar
• Berenbaum F. Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol 2004;16:616-22
   PubMed Web of Science ®Google Scholar
• Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2007
   PubMedGoogle Scholar
• Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 2001;29:4361-72
   PubMed Web of Science ®Google Scholar
• Okazaki K, Li J, Yu H, et al. CCAAT/enhancer-binding proteins beta and delta mediate the repression of gene transcription of cartilage-derived retinoic acid-sensitive protein induced by interleukin-1 beta. J Biol Chem 2002;277:31526-33
   PubMed Web of Science ®Google Scholar
• Masuko-Hongo K, Berenbaum F, Humbert L, et al. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum 2004;50:2829-38
   PubMed Web of Science ®Google Scholar
• Ghayor C, Chadjichristos C, Herrouin JF, et al. Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes. J Biol Chem 2001;276:36881-95
   PubMed Web of Science ®Google Scholar
• Tan L, Peng H, Osaki M, et al. Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1beta. J Biol Chem 2003;278:17688-700
   PubMed Web of Science ®Google Scholar
• Peng H, Tan L, Osaki M, et al. ESE-1 is a potent repressor of type II collagen gene (COL2A1) transcription in human chondrocytes. J Cell Physiol 2007
   PubMedGoogle Scholar
• Gan Q, Yoshida T, McDonald OG, Owens GK. Epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 2006
   PubMedGoogle Scholar
• Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447:425-32
   PubMed Web of Science ®Google Scholar
• Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433-40
   PubMed Web of Science ®Google Scholar
• Pradhan S, Esteve PO. Mammalian DNA (cytosine-5) methyltransferases and their expression. Clin Immunol 2003;109:6-16
   PubMed Web of Science ®Google Scholar
• Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006;31:89-97
   PubMed Web of Science ®Google Scholar
• Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-89
   PubMed Web of Science ®Google Scholar
• Wade PA, Gegonne A, Jones PL, et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999;23:62-6
   PubMed Web of Science ®Google Scholar
• Fujita N, Watanabe S, Ichimura T, et al. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J Biol Chem 2003;278:24132-8
   PubMed Web of Science ®Google Scholar
• Ayyanathan K, Lechner MS, Bell P, et al. Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev 2003;17:1855-69
   PubMed Web of Science ®Google Scholar
• Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005;15:490-5
   PubMed Web of Science ®Google Scholar
• Fuks F, Hurd PJ, Wolf D, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-40
   PubMed Web of Science ®Google Scholar
• Martin C, Zhang Y. Mechanisms of epigenetic inheritance. Curr Opin Cell Biol 2007;19:266-72
   PubMed Web of Science ®Google Scholar
• Newell-Price J, Clark AJ, King P. DNA methylation and silencing of gene expression. Trends Endocrinol Metab 2000;11:142-8
   PubMed Web of Science ®Google Scholar
• Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 2002;59:241-57
   PubMed Web of Science ®Google Scholar
• Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 2007;115:1039-59
   PubMed Web of Science ®Google Scholar
• Richardson B. DNA methylation and autoimmune disease. Clin Immunol 2003;109:72-9
   PubMed Web of Science ®Google Scholar
• Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol 2006;176:7143-7
   PubMed Web of Science ®Google Scholar
• Sekigawa I, Kawasaki M, Ogasawara H, et al. DNA methylation: its contribution to systemic lupus erythematosus. Clin Exp Med 2006;6:99-106
   PubMed Web of Science ®Google Scholar
• Huber LC, Stanczyk J, Jungel A, Gay S. Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum 2007;56:3523-31
   PubMed Web of Science ®Google Scholar
• Sanchez-Pernaute O, Ospelt C, Neidhart M, Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 2008
   PubMedGoogle Scholar
• Petronis A. Human morbid genetics revisited: relevance of epigenetics. Trends Genet 2001;17:142-6
   PubMed Web of Science ®Google Scholar
• Ptak C, Petronis A. Epigenetics and complex disease: from etiology to new therapeutics. Ann Rev Pharmacol Toxicol 2008;48:257-76
   PubMed Web of Science ®Google Scholar
• Bird A. The essentials of DNA methylation. Cell 1992;70:5-8
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis 2007;66:1616-21
   PubMed Web of Science ®Google Scholar
• Poschl E, Fidler A, Schmidt B, et al. DNA methylation is not likely to be responsible for aggrecan down regulation in aged or osteoarthritic cartilage. Ann Rheum Dis 2005;64:477-80
   PubMed Web of Science ®Google Scholar
• Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38:1378-85
   PubMed Web of Science ®Google Scholar
• Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 2006;1:7-13
   PubMed Web of Science ®Google Scholar
• Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest 2007;25:659-65
   PubMed Web of Science ®Google Scholar
• Spector TD, Macgregor AJ. Risk factors for osteoarthritis: genetics. Osteoarthritis Cartilage 2004;12(Suppl A):S39-44
   PubMed Web of Science ®Google Scholar
• Loughlin J. The genetic epidemiology of human primary osteoarthritis: current status. Expert Rev Mol Med 2005;7:1-12
   PubMedGoogle Scholar
• Kirillov A, Kistler B, Mostoslavsky R, et al. A role for nuclear NF-kappaB in B-cell-specific demethylation of the Igkappa locus. Nat Genet 1996;13:435-41
   PubMed Web of Science ®Google Scholar
• Gouze JN, Gouze E, Popp MP, et al. Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther 2006;8:R173
   PubMed Web of Science ®Google Scholar
• Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res 2007;465:241-8
   PubMedGoogle Scholar
• Sharma D, Blum J, Yang X, et al. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 2005;19:1740-51
   PubMed Web of Science ®Google Scholar
• Carvin CD, Parr RD, Kladde MP. Site-selective in vivo targeting of cytosine-5 DNA methylation by zinc-finger proteins. Nucleic Acids Res 2003;31:6493-501
   PubMed Web of Science ®Google Scholar
• Verschure PJ, Visser AE, Rots MG. Step out of the groove: epigenetic gene control systems and engineered transcription factors. Adv Genet 2006;56:163-204
   PubMed Web of Science ®Google Scholar